IDEXX revenue rises 10% to $1.22 billion
- IDEXX reported second-quarter revenue of $1.217 billion, up 10%, while diluted EPS increased 18% to $4.27.
- IDEXX shares were unchanged at $567.84 in the latest available premarket quote.
- The company raised its 2026 EPS outlook to $14.69–$14.94 and narrowed revenue guidance to $4.700–$4.745 billion.
IDEXX Laboratories (NASDAQ:IDXX) reported second-quarter revenue of $1.217 billion, up 10%, while diluted EPS increased 18% to $4.27.
Organic revenue grew 9%, while EPS benefited by $0.14 from share-based compensation tax benefits and $0.06 from currency movements.
Gross margin rose 140 basis points to 64%, operating margin reached 35%, and the inVue Dx installed base surpassed 9,000 instruments.
Following the announcement, IDEXX's share price was unchanged at $567.84, while the company forecast 2026 revenue of $4.7–$4.745 billion.
Meanwhile, CAG Diagnostics' recurring revenue increased 11%, with VetLab consumables up 15% and reference laboratory services growing 11%.
Water revenue also rose 15%, LPD revenue increased 11%, and veterinary software, services and diagnostic imaging revenue grew 12%.
Frequently asked questions
More from United States
Axsome Q3 loss beats estimates as revenue reaches $259.7m
Marvell to acquire Lumentum in $115bn AI deal
Alexander's Q3 FFO reaches $36.3m as revenue hits $72.1m
Pathfinder Bancorp Q3 earnings reach $2.1m as credit costs weigh
Tower Semiconductor Q3 revenue accelerates 33% to $526m
Acadia Realty Q3 NOI rises 10.2% as retail leasing grows
